Patents by Inventor Eduardo Gonzalez Barreda

Eduardo Gonzalez Barreda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
    Patent number: 11137409
    Abstract: In some embodiments, the invention provides methods for detecting an aberrant fibrinolysis condition in a patient. The method includes subjecting a blood sample from the patient to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, the coagulation characteristic value of the healthy individual obtained by subjecting a blood sample from a healthy individual to the viscoelastic analysis in the presence of the known amount of the thrombolytic agent, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patent as having aberrant fibrinolysis.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: October 5, 2021
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Michael P. Chapman, Hunter B. Moore, Eduardo Gonzalez Barreda, Ernest E. Moore
  • Identification of Novel Disease States Using Viscoelastic Analysis in the Presence of an Thrombolytic Agent
    Publication number: 20170336423
    Abstract: In some embodiments, the invention provides methods for detecting an aberrant fibrinolysis condition in a patient. The method includes subjecting a blood sample from the patient to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, the coagulation characteristic value of the healthy individual obtained by subjecting a blood sample from a healthy individual to the viscoelastic analysis in the presence of the known amount of the thrombolytic agent, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patent as having aberrant fibrinolysis.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 23, 2017
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Michael P. Chapman, Hunter B. Moore, Eduardo Gonzalez Barreda, Ernest E. Moore